A BILL 
To require reporting on prescription drug expenditures under 
group health plans and on prescription drug price 
changes, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Prescription Drug 
4
Price Reporting Act’’. 
5
SEC. 2. PRESCRIPTION DRUG PRICE REPORTING REQUIRE-
6
MENTS. 
7
(a) SUBMISSION OF DATA.— 
8
(1) IN GENERAL.—Each manufacturer of a pre-
9
scription drug shall submit to the Secretary, elec-
10
03:09 Dec 06, 2019
H5239
aiking on DSK30JT082PROD with BILLS
2 
•HR 5239 IH
tronically, in such manner as the Secretary may re-
1
quire, by April 1 of each year, a list of each such 
2
drug that is marketed in the United States and, 
3
with respect to each such drug, all of the following 
4
information with respect to the previous year: 
5
(A) Each applicable National Drug Code 
6
(or J–Code). 
7
(B) Brand name. 
8
(C) Generic name and chemical name, as 
9
applicable. 
10
(D) Therapeutic class or classes, as appli-
11
cable. 
12
(E) Current wholesale acquisition cost per 
13
30-day supply or typical course of treatment. 
14
(F) Average wholesale acquisition cost for 
15
the drug per 30-day supply or typical course of 
16
treatment during the previous calendar year, or, 
17
in the case of a drug that has been marketed 
18
for only a portion of such year, during the por-
19
tion of time in such year that the drug was 
20
marketed. 
21
(G) Average net price per 30-day supply or 
22
typical course of treatment, during the previous 
23
calendar year, or, in the case of a drug that has 
24
been marketed for only a portion of such year, 
25
03:09 Dec 06, 2019
H5239
aiking on DSK30JT082PROD with BILLS
3 
•HR 5239 IH
during the portion of time in such year that the 
1
drug was marketed, taking into account all dis-
2
counts, rebates, and other fees or payments to 
3
health insurance plans or pharmacy benefit 
4
managers with respect to sales of the drug to 
5
individuals covered by such a plan. 
6
(H) Total rebates and other payments to 
7
health insurance plans or pharmacy benefit 
8
managers, per 30-day supply or typical course 
9
of treatment, with respect to individuals covered 
10
by such a plan, during the previous calendar 
11
year, or, in the case of a drug that has been 
12
marketed for only a portion of such calendar 
13
year, during the portion of time in such cal-
14
endar year that the drug was marketed. 
15
(2) TIMELINE FOR INITIAL SUBMISSION.— 
16
(A) DRUGS
MARKETED
BEFORE
DECEM-
17
BER
31, 2020.—Each manufacturer of a pre-
18
scription drug that is marketed at any time 
19
during calendar year 2020, shall submit to the 
20
Secretary, not later than April 1, 2021— 
21
(i) the information required under 
22
paragraph (1); and 
23
(ii) in addition to the information re-
24
quired under subparagraphs (F), (G), and 
25
03:09 Dec 06, 2019
H5239
aiking on DSK30JT082PROD with BILLS
4 
•HR 5239 IH
(H) of paragraph (1), such average whole-
1
sale acquisition cost, average net price, and 
2
total rebates and other payments, de-
3
scribed in each of such subparagraphs, re-
4
spectively, with respect to the calendar 
5
year immediately preceding the calendar 
6
year for which such information is required 
7
to be reported under such subparagraphs 
8
(F), (G), and (H). 
9
(B) SUBSEQUENTLY MARKETED DRUGS.— 
10
With respect to a prescription drug that is first 
11
marketed after December 31, 2020, each manu-
12
facturer of such a drug shall submit the infor-
13
mation required under subparagraphs (A) 
14
through (E) of paragraph (1) not later than 60 
15
days after the date on which the drug is first 
16
marketed, and shall submit annual reports of 
17
all of the information required under paragraph 
18
(1) beginning on the first annual reporting date 
19
that is more than 30 days after the date on 
20
which the drug is first marketed. 
21
(b) ADVANCE
NOTIFICATION
OF
PRESCRIPTION 
22
DRUG PRICING CHANGES.— 
23
(1) IN GENERAL.—Each manufacturer of a pre-
24
scription drug shall report to the Secretary, elec-
25
03:09 Dec 06, 2019
H5239
aiking on DSK30JT082PROD with BILLS
5 
•HR 5239 IH
tronically, in such manner as the Secretary may re-
1
quire, any increase or decrease in the wholesale ac-
2
quisition cost of a prescription drug not later than 
3
30 days prior to the date on which the price change 
4
takes effect. 
5
(2) CONTENT.—A price change report under 
6
paragraph (1) shall include— 
7
(A) the information required under sub-
8
paragraphs (A), (B), (C), (D), and (F) of sub-
9
section (a)(1); 
10
(B) the wholesale acquisition cost per 30- 
11
day supply or typical course of treatment imme-
12
diately prior to the price change; 
13
(C) the new wholesale acquisition cost per 
14
30-day supply or typical course of treatment, 
15
when the change takes effect; and 
16
(D) financial and non-financial factors the 
17
manufacturer took into consideration when 
18
making the price change, including any changes 
19
or improvements to the drug. 
20
(c) PUBLIC DATABASE.— 
21
(1) IN GENERAL.—The Secretary shall establish 
22
an internet-based system to post prescription drug 
23
information reported under subsection (a) and price 
24
change reports required under subsection (b). 
25
03:09 Dec 06, 2019
H5239
aiking on DSK30JT082PROD with BILLS
6 
•HR 5239 IH
(2) CONSUMER SUBSCRIPTION OPTIONS.—The 
1
system established under paragraph (1) shall enable 
2
consumers to subscribe to price change notifica-
3
tions— 
4
(A) for— 
5
(i) all drugs; 
6
(ii) a particular drug; or 
7
(iii) a particular therapeutic class of 
8
drugs; and 
9
(B) that are limited to price changes that 
10
are at or over a specified amount. 
11
(3) TIMING.—The prescription drug informa-
12
tion reported under subsection (a) shall be made 
13
publicly available not later than 30 days after being 
14
reported to the Secretary. In the case of a price 
15
change report required under subsection (b), the 
16
Secretary shall make publicly available a notice of 
17
the price change contained in such report on the day 
18
such change takes effect. 
19
(d) PRIVACY PROTECTIONS.—The information sub-
20
mitted under subparagraphs (A) through (F) of subsection 
21
(a)(1) and paragraph (2)(A)(ii) shall be publicly available 
22
through the database established under subsection (c). No 
23
other information submitted to the Secretary pursuant to 
24
subsection (a) or (b) that is proprietary, confidential, or 
25
03:09 Dec 06, 2019
H5239
aiking on DSK30JT082PROD with BILLS
7 
•HR 5239 IH
trade secret information shall be included in such data-
1
base. 
2
(e) DEFINITIONS.—For purposes of this section— 
3
(1) the term ‘‘manufacturer’’ has the meaning 
4
given such term in section 581 of the Federal Food, 
5
Drug, and Cosmetic Act (21 U.S.C. 360eee); 
6
(2) the term ‘‘prescription drug’’ means a drug 
7
approved section 505 of the Federal Food, Drug, 
8
and Cosmetic Act (21 U.S.C. 355) or a biological 
9
product licensed under section 351 of the Public 
10
Health Service Act (42 U.S.C. 262) that is subject 
11
to section 503(b)(1) of the Federal Food, Drug, and 
12
Cosmetic Act (21 U.S.C. 353(b)(1)); 
13
(3) the term ‘‘Secretary’’ means the Secretary 
14
of Health and Human Services; and 
15
(4) the term ‘‘wholesale acquisition cost’’ has 
16
the 
meaning 
given 
such 
term 
in 
section 
17
1847A(c)(6)(B) of the Social Security Act (42 
18
U.S.C. 1395w–3a (c)(6)(B)). 
19
(f) PREEMPTION.—Effective on the date that the 
20
public database under subsection (b)(3) first becomes 
21
operational, no State or political subdivision of a State 
22
may establish or continue in effect any law requiring the 
23
03:09 Dec 06, 2019
H5239
aiking on DSK30JT082PROD with BILLS
8 
•HR 5239 IH
manufacturer to report or make public prescription drug 
1
pricing information. 
2
Æ 
03:09 Dec 06, 2019
H5239
aiking on DSK30JT082PROD with BILLS
